Want to see HK:0157 full AI Analyst Report?
Top Page
Natural Beauty Bio-Technology
(0157)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$0.46
â–²(3.64% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily held back by weak financial quality—especially persistent negative free cash flow and negative operating cash flow in 2025—despite a rebound in revenue and a return to modest profitability. Technicals are broadly neutral (price near moving averages; RSI near 52), while valuation is a headwind due to the very high P/E and no dividend yield data.
Positive Factors
Revenue Rebound
A clear revenue rebound indicates renewed end-market demand and successful commercial traction after prior flat years. Sustained top-line growth provides the foundation for margin recovery, better absorption of fixed costs and scaling of marketing and distribution investments over the next 2–6 months.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow across multiple years indicates the business is not converting accounting profits into cash. This structural cash burn raises financing and liquidity risk, forces reliance on external funding and constrains durable reinvestment in product, stores or marketing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
A clear revenue rebound indicates renewed end-market demand and successful commercial traction after prior flat years. Sustained top-line growth provides the foundation for margin recovery, better absorption of fixed costs and scaling of marketing and distribution investments over the next 2–6 months.
Read all positive factors
Natural Beauty Bio-Technology (0157) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$910.96M
Dividend Yield0.53%
Average Volume (3M)49.33K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth13.43%
EPS Growth7.72%
CountryHK
Employees597
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,002,101,000
10 Day Avg. Volume41,000
30 Day Avg. Volume49,333
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)2.07
Price to Sales (P/S)1.82
P/FCF Ratio-10.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Natural Beauty Bio-Technology Business Overview & Revenue Model
Company Description
Natural Beauty Bio-Technology Limited operates as an investment holding company, supplying skincare products and a comprehensive range of services across the People's Republic of China, Taiwan, and other global regions. Under its "Natural Beauty" ...
How the Company Makes Money
null...
Natural Beauty Bio-Technology Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
66
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.38M | 538.83M | 353.65M | 336.01M | 335.88M | 487.81M |
| Gross Profit | 227.26M | 293.34M | 202.33M | 200.34M | 165.33M | 281.80M |
| EBITDA | 458.00K | 57.78M | -65.50M | 22.91M | 15.09M | 85.23M |
| Net Income | -57.48M | 10.58M | -103.61M | -15.11M | -30.47M | 35.26M |
Balance Sheet | ||||||
| Total Assets | 1.01B | 931.55M | 772.93M | 882.58M | 883.53M | 937.16M |
| Cash, Cash Equivalents and Short-Term Investments | 116.16M | 112.12M | 116.51M | 166.81M | 168.61M | 197.08M |
| Total Debt | 424.66M | 319.30M | 212.13M | 186.29M | 143.48M | 129.07M |
| Total Liabilities | 587.05M | 457.56M | 325.34M | 308.06M | 286.07M | 279.24M |
| Stockholders Equity | 423.52M | 473.98M | 447.59M | 574.52M | 597.46M | 657.92M |
Cash Flow | ||||||
| Free Cash Flow | -136.88M | -93.91M | -54.96M | -47.39M | -35.98M | 4.67M |
| Operating Cash Flow | -58.33M | -25.66M | -13.75M | 21.72M | 8.33M | 42.78M |
| Investing Cash Flow | -74.73M | -68.95M | -40.17M | -67.61M | -38.77M | -31.21M |
| Financing Cash Flow | 169.03M | 84.61M | 15.34M | 42.63M | 13.21M | 10.42M |
Natural Beauty Bio-Technology Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$521.12M | 6.13 | 6.06% | 9.79% | 2.24% | -39.98% | |
75 Outperform | HK$9.17B | 11.74 | 25.72% | 5.95% | 23.19% | -22.44% | |
65 Neutral | HK$25.05B | 8.75 | 10.98% | 7.42% | 2.19% | 10.78% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | HK$910.96M | -15.85 | -12.81% | 0.53% | 13.43% | 7.72% | |
38 Underperform | HK$20.78B | -233.23 | -1.21% | 4.18% | -2.44% | 81.73% |
* Consumer Defensive Sector Average
HK:0157
Natural Beauty Bio-Technology
0.46
-0.09
-15.74%
HK:1044
Hengan International Group Co
21.58
-1.82
-7.79%
HK:3828
Ming Fai International Holdings
0.72
-0.23
-24.18%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
23.60
-70.61
-74.95%
HK:6993
Blue Moon Group Holdings Ltd.
3.83
0.61
18.90%
HK:6883
Eternal Beauty Holdings Limited
2.03
-0.07
-3.33%
Natural Beauty Bio-Technology Corporate Events
Natural Beauty Bio-Technology calls EGM to approve new multi-year cooperation deals
Aug 3, 2026
Natural Beauty Bio-Technology has convened an extraordinary general meeting in Taipei on 24 August 2026 to seek shareholder approval for three major cooperation and supply agreements running from 1 September 2026 to 31 August 2029. The ET New Medi...
Natural Beauty Bio-Technology Further Delays Circular on Connected Transactions
Jul 29, 2026
Natural Beauty Bio-Technology Limited has announced a further delay in sending a shareholder circular related to the renewal of its continuing connected transactions. The company had previously indicated the circular would be dispatched by 27 July...
Natural Beauty Bio-Technology warns of first-half loss amid expansion costs
Jul 24, 2026
Natural Beauty Bio-Technology has warned that it expects to swing to a net loss of about HK$56 million to HK$59 million for the first half of 2026, compared with a net profit of HK$10.9 million a year earlier. The deterioration reflects a 5.84% dr...
Natural Beauty Bio-Technology Sets August Board Meeting on Interim Results and Dividend
Jul 17, 2026
Natural Beauty Bio-Technology Limited has scheduled a board meeting for 6 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026. The board will also consider the payment of an interim dividend, i...
Natural Beauty Bio-Technology Delays Circular on Connected Transactions
Jul 6, 2026
Natural Beauty Bio-Technology Limited has announced a delay in sending a shareholder circular related to the renewal of its continuing connected transactions. The circular, initially expected to be despatched by 6 July 2026, will now be sent on or...
Natural Beauty Bio-Technology Wins Unanimous Shareholder Backing at AGM
Jun 25, 2026
Natural Beauty Bio-Technology reported that all resolutions at its 25 June 2026 annual general meeting were passed by poll with 100% support from voting shareholders. The meeting approved the 2025 audited financial statements, re-elected the full ...
Natural Beauty Renews Connected Deals, Triggers Shareholder Vote Under HK Rules
Jun 12, 2026
Natural Beauty Bio-Technology has renewed a series of continuing connected transaction agreements between its subsidiaries Taiwan NB and NB China and several related parties, including ET New Media, Eastern Home, Eastern Global, ET New Retail and ...
Natural Beauty Bio-Technology Sets AGM to Approve Accounts, Board and Share Buy-Back Mandate
Jun 3, 2026
Natural Beauty Bio-Technology has called its annual general meeting for 25 June 2026 in Taipei, where shareholders will review the group’s audited consolidated financial statements and the board and auditor reports for the year ended 31 Dece...
Natural Beauty Bio-Technology Strengthens Board to Meet Governance Rules
May 26, 2026
Natural Beauty Bio-Technology has strengthened its board by appointing veteran Taiwanese public servant and corporate director Mr. Duh Tyzz-Jiun as an independent non-executive director, effective 25 May 2026. He will also sit on the audit and nom...
Natural Beauty Bio-Technology Reshapes Board and Committee Structure
May 26, 2026
Natural Beauty Bio-Technology has updated the composition of its board of directors with effect from 25 May 2026, naming Dr. Lei Chien as chairperson alongside executive, non-executive, and independent non-executive directors. The company also det...
Natural Beauty Bio-Technology Reshapes Board and Committee Roles
May 15, 2026
Natural Beauty Bio-Technology Limited has updated the composition of its board of directors effective 16 May 2026, naming Dr. Lei Chien as chairperson and confirming a mix of executive, non-executive, and independent non-executive directors. The c...
Natural Beauty Bio-Technology Announces Board Reshuffle and Confirms Governance Compliance
May 15, 2026
Natural Beauty Bio-Technology announced that executive director Mr. Lin Chia-Wei will resign on 16 May 2026 from the board, its nomination, remuneration and executive committees, and his role as authorised representative, citing the need to focus ...
Natural Beauty Bio-Technology Faces Governance Gap After Independent Director Exit
May 11, 2026
Natural Beauty Bio-Technology Limited announced that independent non-executive director Mr. Chen Ruey-Long has resigned, effective 8 May 2026, stepping down as chairman of the Audit Committee and as a member of the Nomination and Remuneration Comm...
Natural Beauty Bio-Technology Updates Board and Committee Structure
May 11, 2026
Natural Beauty Bio-Technology Limited has outlined the current composition of its board, naming Dr. Lei Chien as chairperson alongside executive, non-executive and independent non-executive directors, reflecting a diversified governance structure....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.